• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $GNTA

    Genenta Science S.p.A.

    Subscribe to $GNTA
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: https://www.genenta.com

    Recent Analyst Ratings for Genenta Science S.p.A.

    DatePrice TargetRatingAnalyst
    6/29/2023$15.00Buy
    ROTH MKM
    7/25/2022$25.00Buy
    H.C. Wainwright
    See more ratings

    Genenta Science S.p.A. Leadership Updates

    Live Leadership Updates

    See more
    • ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

      Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector1 SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. The event will take place at INNOVIT (710 Sansome Street), San Francisco's Italian Innovation and Culture Hu

      1/8/25 3:17:00 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

      MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

      5/6/24 6:25:00 AM ET
      $ARYD
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

      Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

      1/17/23 8:00:00 AM ET
      $AGRX
      $GNTA
      $NMTR
      $PG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Package Goods/Cosmetics
    • Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

      MILAN, Italy and NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces the appointment of Tim Obara, a highly experienced commercial healthcare executive, as Vice President Business Development. Tim has significant experience across a broad range of therapeutic areas and with global responsibility. He joins Genenta from the University of Pennsylvania Gene Therapy Program, where he was Executive Director of Research Operations. He has previously worked in senior business development roles at Amicus Therapeutics, AstraZeneca, G

      5/9/22 7:30:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Genenta Science S.p.A. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

      MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) based in Italy. This strategic partnership marks a major milestone, encompassing the successful production of critical starting materials, including the establishment of Cell Banks and the manufacturing of Plasmids for viral vector production. This collaboration represents a pivotal step in the advancement of immuno-oncology therapies, highlighting the powerful synergy between Genenta's innovative platform and Anemocyte's proven exper

      5/7/25 7:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

      MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at "Montalcini Global Biotech Tour" in Doha, Qatar on April 17th, 2025 at the Sheikh Fahad bin Jassim Al Thani theatre, Ministry of Commerce and Industry (MOCI) Building. Following the announcement of a €20 million ($22.7 million) strategic financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) — aimed at expanding Genenta's pipeline with the advancement of Temferon™ in metastatic Renal Cell Cancer (mRCC) — and the addition of approximately €3.0 million

      4/15/25 5:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

      MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) to support the expansion of its pipeline by advancing Temferon in metastatic Renal Cell Cancer (mRCC). ETB is a leading private foundation, supervised by the Italian Ministry of Enterprises and Made in Italy, managing over €1,7 billion in assets under management through two funds. With deep expertise in the biomedical sector, ETB is an established authority in identifying and supporting high-pote

      3/19/25 9:28:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

      USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 27, 2025 /PRNewswire/ -- USA News Group News Commentary – Now that World Cancer Day (Feb. 4) has come and gone, the world and the market are looking towards what's being discussed among oncology experts around the world. Recently, the New York Times put out a report asking big questions about cancer and its treatments, including about the impact of pollution (including microplastics) on cancer rates, genetic mutations, and inflammation. In the UK, The Guardian reported research showing a need for further studies into air pollution as lung cancer diagnoses are on the rise among never-smokers worldwide. As

      2/27/25 10:04:00 AM ET
      $AMGN
      $CELC
      $GNTA
      $ONCY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
      Biotechnology: Pharmaceutical Preparations
    • Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

      MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened its partnership with AGC Biologics, a global contract development and manufacturing organization (CDMO), by amending their Development and Master Services Agreement. This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta's cell therapy product, ensuring compliance with cGMP standards. This strategic move enhances Genenta's production capabilities, potentially improving efficiency and reliab

      1/9/25 6:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

      Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector1 SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. The event will take place at INNOVIT (710 Sansome Street), San Francisco's Italian Innovation and Culture Hu

      1/8/25 3:17:00 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective"

      MILAN and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and in cell-based therapeutics, is pleased to announce that Pierluigi Paracchi, CEO, will attend as a speaker to the Italy-U.S. meeting "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective" scheduled at 2.00 PM on October 25th, 2024 at the U.S. Senate - Washington, D.C. The event is organized by the U.S. National Security Commission on Emerging Biotechnology (NSCEB) and the Italian Embassy in the U.S. The upcoming mission to Washington, D.C. is part of the strategic plan of the Italian Working Group on the Internationalizati

      10/23/24 7:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

      MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), marking a significant expansion of the potential applications for Genenta's flagship product, Temferon™. This approval by AIFA is in line with the standards that are harmonized across European regulatory frameworks established by the European Medicines Agency (EMA). From the CEO's Desk: Pierluigi Paracchi, CEO and Co-founder of Genenta, stated: "This approval to initiate a Phase 1 trial i

      10/2/24 6:30:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

      MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

      5/6/24 6:25:00 AM ET
      $ARYD
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

      MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that: We have successfully dosed the first of three patients in Cohort 8 (Temferon™ at 4x10^6/kg), the last cohort of the Phase 1 dose-ranging part of the Phase 1/2 clinical trial in newly diagnosed uMGMT Glioblastoma Multiforme (TEM-GBM) patients. The second patient has been enrolled and the treatment is planned. Thus far, the preliminary data indicate no dose-limiting toxicities related to Temfero

      2/8/24 5:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Genenta Science S.p.A. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

      SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

      2/12/24 4:05:34 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

      SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

      2/10/23 6:02:50 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Genenta Science S.p.A.

      SC 13G - Genenta Science S.p.A. (0001838716) (Subject)

      2/25/22 1:17:49 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Genenta Science S.p.A.

      SC 13G - Genenta Science S.p.A. (0001838716) (Subject)

      2/18/22 4:38:50 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Genenta Science S.p.A.

      SC 13G - Genenta Science S.p.A. (0001838716) (Subject)

      2/14/22 2:42:25 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Genenta Science S.p.A. SEC Filings

    See more
    • SEC Form 424B5 filed by Genenta Science S.p.A.

      424B5 - Genenta Science S.p.A. (0001838716) (Filer)

      3/28/25 4:30:29 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 20-F filed by Genenta Science S.p.A.

      20-F - Genenta Science S.p.A. (0001838716) (Filer)

      3/28/25 4:25:59 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genenta Science S.p.A.

      6-K - Genenta Science S.p.A. (0001838716) (Filer)

      3/19/25 9:27:03 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genenta Science S.p.A.

      6-K - Genenta Science S.p.A. (0001838716) (Filer)

      3/19/25 9:26:03 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genenta Science S.p.A.

      6-K - Genenta Science S.p.A. (0001838716) (Filer)

      12/30/24 4:05:26 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genenta Science S.p.A.

      6-K - Genenta Science S.p.A. (0001838716) (Filer)

      12/20/24 4:27:16 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Genenta Science S.p.A.

      424B5 - Genenta Science S.p.A. (0001838716) (Filer)

      12/20/24 4:05:33 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genenta Science S.p.A.

      6-K - Genenta Science S.p.A. (0001838716) (Filer)

      12/13/24 4:05:15 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genenta Science S.p.A.

      6-K - Genenta Science S.p.A. (0001838716) (Filer)

      11/14/24 4:02:59 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genenta Science S.p.A.

      6-K - Genenta Science S.p.A. (0001838716) (Filer)

      10/29/24 4:17:33 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Genenta Science S.p.A. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM resumed coverage on Genenta S.p.A. with a new price target

      ROTH MKM resumed coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $15.00

      6/29/23 9:11:48 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Genenta S.p.A. with a new price target

      H.C. Wainwright initiated coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $25.00

      7/25/22 7:15:53 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care